Showing results (871-880 of 919) with videos related to

Sort By:
Pageof 92
Molecular Cancer Therapeutics|August 24, 2023
SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma IndicationsRobert P Lyon, Mechthild Jonas, Christopher Frantz, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 14, 2020
Prediction of Transporter-Mediated Rosuvastatin Hepatic Uptake Clearance and Drug Interaction in Humans Using Proteomics-Informed REF ApproachVineet Kumar, Mengyue Yin, Kazuya Ishida, et al.
Plos One|October 14, 2009
Updating phylogeny of mitochondrial DNA macrohaplogroup m in India: dispersal of modern human in South Asian corridorAdimoolam Chandrasekar, Satish Kumar, Jwalapuram Sreenath, et al.
Global Health, Science and Practice|December 23, 2022
Does Quality Certification Work? An Assessment of Manyata, a Childbirth Quality Program in India's Private SectorMegan Marx Delaney, Gulnoza Usmanova, Tapas Sadasivan Nair, et al.
Science (New York, N.Y.)|May 13, 2022
Control of meiotic chromosomal bouquet and germ cell morphogenesis by the zygotene ciliumAvishag Mytlis, Vineet Kumar, Tao Qiu, et al.
Journal of Global Antimicrobial Resistance|December 14, 2025
Integrative machine learning approaches with genomic data for predicting antitubercular drug resistance: A systematic review and meta-analysisRohan Shrivastava, Kashmi Sharma, Somesh Mishra, et al.
International Journal of Biological Macromolecules|July 10, 2025
Doxorubicin loaded salicylic acid crosslinked chitosan nanoparticles as postsurgical implants for breast cancerTushar Kanti Rajwar, Rakesh Kumar Sahoo, Jitu Halder, et al.
Cell Chemical Biology|March 13, 2021
Y box binding protein 1 inhibition as a targeted therapy for ovarian cancerDhanir Tailor, Angel Resendez, Fernando Jose Garcia-Marques, et al.
Current Pharmaceutical Design|November 15, 2024
Therapeutic Potential of Neutralizing Monoclonal Antibodies (nMAbs) against SARS-CoV-2 Omicron VariantPijus Parua, Somnath Ghosh, Koushik Jana, et al.
Journal of Medicinal Chemistry|September 12, 2014
Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cellsMirko Andreoli, Marco Persico, Ajay Kumar, et al.
Pageof 92